Gutbrodt Activity Against Acute Myeloid Leukemia Antibody-Based Delivery of Interleukin-2 to Neovasculature Has Potent

confirm efficacy. cells. Early results from clinical trials support these results in human patients, although further trials are needed to T + Indeed, this effect was long-lasting in immunocompetent mice and was mediated by both natural killer and CD8 inhibit AML progression. The effect was further enhanced by combination with the chemotherapeutic cytarabine. took this observation into mouse models and found that if they fused interleukin-2 to the targeting antibody, they could these vessels could be stained by clinical-stage human antibodies against tumor angiogenesis markers. They then The authors observed that AML patients have increased blood vessel density in the bone marrow, and that patients with acute myeloid leukemia (AML) has activity against blood-borne cancers as well. find that targeting neovascular structures found in the bone marrow of et al. tumors like leukemias. Now, Gutbrodt development. However, angiogenesis-targeting therapy has been relatively neglected in the context of blood-borne nutrients to all parts of the tumors, and targeting these new vessels has long been a focus of cancer therapy is thought to be critical to bring oxygen and −− angiogenesis −− For solid tumors, new blood vessel formation The Blood Mobile